Abetimus
 | |
| Clinical data | |
|---|---|
| Trade names | Riquent |
| ATC code | |
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C1632H1944N610Na156O970P156S4 |
| Molar mass | 54171.35 g·mol−1 |
  (what is this?) (verify) | |
Abetimus (trade name Riquent) is an
systemic lupus erythematosus and specifically lupus nephritis
.
It was developed by La Jolla Pharmaceutical, who applied for marketing authorisations in the mid-2000s, but the drug was never marketed in the US or in Europe.[3][4]
References
- S2CID 19896886.
- S2CID 43518002.
- ^ "Riquent Approval Status". Drugs.com. Retrieved 7 January 2017.
- ^ "Riquent". European Medicines Agency. Retrieved 7 January 2017.